To address the dual bottlenecks of immunosuppressive cell infiltration and impaired T-cell function in the tumor microenvironment (TME), researchers from the School of Pharmaceutical Sciences of Sun Yat-sen University (China) aimed to develop an engineered bispecific peptide-nanozyme conjugate (BsPNEC) targeting PD-L1 and CXCR1/2.